Chronic Kidney Disease. Chronic kidney disease (CKD)
Conditions
Interventions
Intervention 1: Intervention group 1: administration of dapagliflozin at a dose of 10 mg daily for 6 months in stage 1 chronic kidney disease patients. Intervention 2: Intervention group 2 : administr
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with chronic kidney disease (CKD) based on laboratory findings and confirmed by a nephrologist with a GFR greater than 20 ml/min/1.73m2 with and without type 2 diabetes Patients with chronic kidney disease (CKD) and on ACEI or ARB treatment Age 20 to 80 years Absence of immune deficiency Absence of diabetes type 1 No kidney transplant Not suffering from Stage 5 of CKD: dialysis and non-dialysis Not taking dapagliflozin before starting the study Not taking other SGLT2 inhibitors before starting the study
Exclusion criteria
Exclusion criteria: Reaching Stage 5 Start of dialysis Failure to take medication regularly Having an acute illness in the course of the investigation that affects the GFR, such as a drop in ejection fraction after a heart attack (MI), viral diseases and sepsis, dehydration and nausea and vomiting The development of AKI caused by the use of the drug (temporary increase in creatinine) or UTI following the use of this drug Taking nephrotoxic drugs such as aminoglycosides, NSAIDs, contrast agents, etc Migration from Arak city
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glomerular Filtration rate based on creatinine. Timepoint: At the beginning of the study, 3 months and 6 months after intervention. Method of measurement: Calculating GFR by CKD-EPI formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum BUN. Timepoint: At the beginning of the study, 3 months and 6 months after intervention. Method of measurement: Routine blood tests.;Proteinuria. Timepoint: At the beginning of the study, 3 months and 6 months after intervention. Method of measurement: Urine analysis.;Albuminuria. Timepoint: At the beginning of the study, 3 months and 6 months after intervention. Method of measurement: Urine analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMorvarid Khoeeniha
Arak University of Medical Sciences
Outcome results
None listed